Harrow Health, Inc. (HROW) Financial Ratios
20 years of historical data (2006–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↓
30.90
↓-50% vs avg
5yr avg: 61.46
30Y Low34.4·High88.7
P/FCF
37.18
↓-11% vs avg
5yr avg: 41.91
30Y Low41.9·High41.9
P/B Ratio
↑
30.25
↑+63% vs avg
5yr avg: 18.62
30Y Low0.7·High34.6
ROE
↑
-8.5%
↓+83% vs avg
5yr avg: -50.6%
30Y Low-470%·High107%
Debt/EBITDA
↓
4.38
↓-72% vs avg
5yr avg: 15.63
30Y Low4.4·High23.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
HROW Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Harrow Health, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 37.2x P/FCF, 11% below the 5-year average of 41.9x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.6B | $1.8B | $1.2B | $365M | $405M | $231M | $178M | $206M | $135M | $34M | $32M |
| Enterprise Value | $1.8B | $2.0B | $1.4B | $482M | $421M | $267M | $197M | $222M | $144M | $45M | $37M |
| P/E Ratio → | -306.21 | — | — | — | — | — | — | 778.00 | 9.33 | — | — |
| P/S Ratio | 5.87 | 6.61 | 5.99 | 2.81 | 4.58 | 3.19 | 3.63 | 4.02 | 3.27 | 1.27 | 1.60 |
| P/B Ratio | 30.25 | 34.58 | 17.26 | 5.22 | 14.88 | 21.15 | 6.62 | 7.51 | 5.47 | 13.02 | 4.95 |
| P/FCF | 37.18 | 41.91 | — | — | — | — | — | — | — | — | — |
| P/OCF | 36.43 | 41.06 | — | 95.13 | 237.73 | 45.49 | — | 216.74 | 197.22 | — | — |
P/E links to full P/E history page with 30-year chart
HROW EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Harrow Health, Inc.'s enterprise value stands at 30.9x EBITDA, 50% below its 5-year average of 61.5x. The Healthcare sector median is 14.2x, placing the stock at a 117% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.27 | 6.90 | 3.70 | 4.76 | 3.68 | 4.03 | 4.34 | 3.48 | 1.69 | 1.84 |
| EV / EBITDA | 30.90 | 34.43 | 62.98 | 41.64 | 88.69 | 79.57 | 87.43 | — | — | — | — |
| EV / EBIT | 46.03 | 51.29 | 151.81 | 593.99 | 219.53 | 79.38 | 263.46 | — | — | — | — |
| EV / FCF | — | 46.08 | — | — | — | — | — | — | — | — | — |
HROW Profitability
Margins and return-on-capital ratios measuring operating efficiency
Harrow Health, Inc. earns an operating margin of 14.2%. Operating margins have expanded from 0.3% to 14.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -8.5% indicates the company is currently destroying shareholder equity. ROIC of 12.0% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.1% | 75.1% | 75.3% | 69.6% | 71.3% | 74.9% | 70.4% | 67.3% | 60.1% | 49.6% | 50.7% |
| Operating Margin | 14.2% | 14.2% | 4.4% | 0.3% | 2.2% | 2.2% | 0.8% | -9.4% | -12.6% | -45.4% | -79.6% |
| Net Profit Margin | -1.9% | -1.9% | -8.8% | -18.7% | -15.9% | -24.8% | -6.9% | 0.3% | 35.4% | -44.8% | -95.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.5% | -8.5% | -25.1% | -50.2% | -73.8% | -95.4% | -12.4% | 0.6% | 106.9% | -264.9% | -756.4% |
| ROA | -1.3% | -1.3% | -5.0% | -10.4% | -11.0% | -23.1% | -5.8% | 0.3% | 39.9% | -46.8% | -92.3% |
| ROIC | 12.0% | 12.0% | 3.0% | 0.3% | 3.2% | 2.6% | 0.6% | -9.3% | -16.6% | -72.4% | -153.2% |
| ROCE | 12.9% | 12.9% | 3.2% | 0.2% | 1.7% | 2.4% | 0.8% | -11.4% | -18.7% | -68.6% | -121.7% |
HROW Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Harrow Health, Inc. carries a Debt/EBITDA ratio of 4.4x, which is highly leveraged (36% above the sector average of 3.2x). Net debt stands at $179M ($252M total debt minus $73M cash). Interest coverage of just 1.6x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 4.84 | 4.84 | 3.30 | 2.72 | 4.12 | 7.13 | 0.88 | 0.77 | 0.62 | 5.86 | 2.13 |
| Debt / EBITDA | 4.38 | 4.38 | 10.46 | 16.47 | 23.63 | 23.24 | 10.44 | — | — | — | — |
| Net Debt / Equity | — | 3.44 | 2.62 | 1.66 | 0.59 | 3.27 | 0.72 | 0.59 | 0.35 | 4.32 | 0.75 |
| Net Debt / EBITDA | 3.11 | 3.11 | 8.30 | 10.06 | 3.36 | 10.67 | 8.62 | — | — | — | — |
| Debt / FCF | — | 4.17 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 1.60 | 1.60 | 0.40 | 0.04 | 0.26 | 0.62 | 0.33 | -0.28 | -1.91 | -4.02 | -5.55 |
HROW Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Harrow Health, Inc.'s current ratio of 2.20x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 2.82x to 2.20x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.20 | 2.20 | 2.08 | 2.82 | 6.35 | 6.24 | 3.79 | 2.99 | 2.76 | 1.53 | 1.49 |
| Quick Ratio | 2.06 | 2.06 | 1.96 | 2.60 | 6.00 | 5.81 | 3.43 | 2.72 | 2.61 | 1.14 | 1.30 |
| Cash Ratio | 0.76 | 0.76 | 0.52 | 1.68 | 5.47 | 5.21 | 3.03 | 2.44 | 2.36 | 0.70 | 0.89 |
| Asset Turnover | — | 0.68 | 0.51 | 0.42 | 0.56 | 0.74 | 0.85 | 0.87 | 0.84 | 1.12 | 0.73 |
| Inventory Turnover | 5.02 | 5.02 | 4.60 | 3.65 | 3.88 | 4.32 | 3.65 | 5.07 | 9.01 | 6.00 | 5.34 |
| Days Sales Outstanding | — | 148.65 | 213.21 | 102.30 | 26.32 | 22.75 | 19.88 | 14.33 | 17.33 | 22.14 | 53.46 |
HROW Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Harrow Health, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | 0.1% | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 0.1% | 10.7% | — | — |
| FCF Yield | 2.7% | 2.4% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $37M | $36M | $33M | $27M | $27M | $26M | $26M | $24M | $20M | $13M |
Peer Comparison
Compare HROW with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 HROWYou | $2B | -306.2 | 30.9 | 37.2 | 75.1% | 14.2% | -8.5% | 12.0% | 4.4 |
 PAHC | $1B | 26.8 | 12.7 | 30.9 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 NUVL | $9B | -21.1 | — | — | — | — | -36.7% | -32.5% | — |
 SGHT | $287M | -7.1 | — | — | 86.2% | -48.0% | -50.7% | -274.4% | — |
 ICUI | $4B | 4774.5 | 14.1 | 38.2 | 36.8% | 4.8% | 0.0% | 2.5% | 4.3 |
 ATRC | $1B | -120.0 | 80.7 | 30.2 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 LNTH | $7B | 30.5 | 16.8 | 19.1 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 PRGO | $1B | -1.0 | 7.1 | 9.8 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 SUPN | $3B | -65.3 | 45.1 | 55.6 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 MCK | $90B | 19.6 | 13.2 | 15.8 | 3.6% | 1.6% | — | 254.1% | 1.2 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 20 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
HROW — Frequently Asked Questions
Quick answers to the most common questions about buying HROW stock.
What is Harrow Health, Inc.'s P/E ratio?
Harrow Health, Inc.'s current P/E ratio is -306.2x. The historical average is 9.3x.
What is Harrow Health, Inc.'s EV/EBITDA?
Harrow Health, Inc.'s current EV/EBITDA is 30.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 65.8x.
What is Harrow Health, Inc.'s ROE?
Harrow Health, Inc.'s return on equity (ROE) is -8.5%. The historical average is -109.6%.
Is HROW stock overvalued?
Based on historical data, Harrow Health, Inc. is trading at a P/E of -306.2x. Compare with industry peers and growth rates for a complete picture.
What are Harrow Health, Inc.'s profit margins?
Harrow Health, Inc. has 75.1% gross margin and 14.2% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Harrow Health, Inc. have?
Harrow Health, Inc.'s Debt/EBITDA ratio is 4.4x, indicating high leverage. A ratio above 4x may signal elevated financial risk.